High early burden of post-stroke spasticity and persistent treatment gaps in structured follow-up care.
Stuckart Isabella I, Schoene Daniela D, Altarsha Eyad E, Pfaff Nastasja N et al.
Post-stroke spasticity (PSS) is a frequent and disabling complication after stroke. Real-world data on the implementation of guideline-recommended antispastic treatment within structured follow-up programs are limited. In this prospective cohort study, patients with persistent motor deficits after stroke were followed within a structured post-stroke care program. Spasticity was assessed using the Modified Ashworth Scale (MAS) at predefined follow-up intervals (3 and 12 months after stroke onset). Clinically relevant spasticity was defined as MAS ≥ 2 in at least one joint. Antispastic treatments, including botulinum toxin type A (BoNT-A), were recorded. The implementation gap for BoNT-A was defined as the proportion of patients with a treatment recommendation who had not initiated therapy. Using a cumulative 12-month MAS-based definition among patients with persistent paresis and available follow-up assessments, clinically relevant spasticity was observed in 40/55 patients (72.7%, 95% CI 59-83.9), while 51/55 patients (92.7%, 95% CI 82.4-97.9) showed any increase in muscle tone (MAS > 0). Clinically relevant spasticity was present in 34/53 patients at 3 months (64.2%, 95% CI 49.8-76.9) and in 26/46 patients at 12 months (56.5%, 95% CI 41.1-71.1). Among patients with clinically relevant spasticity, BoNT-A treatment was recommended in 11.8% at 3 months and 26.9% at 12 months, while no patient with a documented recommendation had initiated therapy. PSS occurs early and affects a substantial proportion of patients with persistent motor deficits after stroke. Despite structured follow-up and systematic screening, implementation of guideline-recommended BoNT-A therapy remained absent in patients with documented treatment recommendations, indicating substantial barriers to evidence-based outpatient spasticity care.